2016
A Double Blind Investigation of Efficacy and Safety of IncobotulinumtoxinA in Parkinson Disease Tremor- A Customized Injection Approach (S40.007)
Mittal S, Rostami R, Machado D, Richardson D, Jabbari B. A Double Blind Investigation of Efficacy and Safety of IncobotulinumtoxinA in Parkinson Disease Tremor- A Customized Injection Approach (S40.007). Neurology 2016, 86 DOI: 10.1212/wnl.86.16_supplement.s40.007.Peer-Reviewed Original ResearchDouble-blind investigationSafety of incobotulinumtoxinAParkinson's disease tremorBlind investigationIncobotulinumtoxinA
2010
High dose D-serine in the treatment of schizophrenia
Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, D'Souza C, Saksa J, Woods SW, Javitt DC. High dose D-serine in the treatment of schizophrenia. Schizophrenia Research 2010, 121: 125-130. PMID: 20541910, PMCID: PMC3111070, DOI: 10.1016/j.schres.2010.05.012.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnalysis of VarianceAntipsychotic AgentsChi-Square DistributionCognition DisordersDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansMaleMiddle AgedNeuropsychological TestsPsychiatric Status Rating ScalesRegression AnalysisSchizophreniaSerineTreatment OutcomeYoung AdultConceptsD-serineBrain N-methyl-D-aspartate receptorsPlasma D-serine levelsN-methyl-D-aspartate receptorsSafety of dosesSignificant dose-dependent increaseDouble-blind investigationOpen-label trialDose-escalation studyDouble-blind studyLarge effect size improvementsTreatment of schizophreniaD-serine levelsPotential novel treatmentPharmacokinetics/pharmacodynamicsDose-dependent increaseNon-significant improvementEffect size improvementsMedication phasePersistent symptomsEscalation studyBrain levelsPlasma levelsPK analysisNeurocognitive dysfunction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply